Filderstadt

Researchers are evaluating the real-world effectiveness, safety, and tolerability of ribociclib combined with an aromatase inhibitor, with or without luteinizing hormone-releasing hormone (LHRH) therapy, for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. The study also compares data from patients treated with abemaciclib plus endocrine therapy with or without LHRH, and those receiving endocrine monotherapy with or without LHRH. This observational study aims to understand treatment decisions and clinical use of ribociclib after its approval, collecting socio-economic data, quality of life, and patient compliance information. Participants receive treatment based on their physician's clinical judgment without study-assigned interventions. The treatments observed include ribociclib with an aromatase inhibitor LHRH, abemaciclib with endocrine therapy LHRH, or endocrine monotherapy LHRH. The study is conducted in various breast cancer centers and gynecological practices in Germany and Austria to represent local healthcare settings. Participants undergo assessments to monitor treatment effectiveness, safety, quality of life, and adherence to therapy over time. Data collected include clinical outcomes, adverse events, socio-economic status, and patient-reported compliance. The primary outcome measured is invasive disease-free survival over 36 months. This information will help inform clinical decision-making and improve outcomes for patients with early breast cancer in routine practice.

This research aims to observe the frequency of antibiotic prescriptions in children hospitalized with community-acquired pneumonia. It focuses on how doctors decide whether or not to use antibiotics in these cases, especially in a pediatric setting with a practice of limited antibiotic use. The study also records parent satisfaction regarding the treatment their child receives. Children admitted to the pediatric departments of the Filderklinik or Herdecke Community Hospital with pneumonia are enrolled consecutively. They are treated following the hospital's standard procedures, which may include either antibiotic treatment or no antibiotic treatment. The study monitors antibiotic treatment rates, disease severity, medical complications, and factors influencing physicians' decisions on antibiotic use. Throughout the hospitalization, researchers track antibiotic treatment rates and document parental satisfaction. Parents are contacted at least four weeks after discharge to check for any recurrence of pneumonia or readmission. The main outcome measure is the rate of antibiotic treatment during the hospital stay, which typically lasts an average of seven days.